Evidence map›Paper›PMID 26156206›Full record

ReviewInternational urogynecology journal2016

Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis.

Federica Puccini, Alka Bhide, Suzy Elneil, G Alessandro Digesu

Abstract readReview
PubMed Publisher
In one paragraph

Review in International urogynecology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Neuromodulation in neurogenic bladder.Translational andrology and urology · 2016
    Review
  6. Is there a role for sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction?International braz j urol : official journal of the Brazilian Society of Urology
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Federica PucciniS. Andrea Hospital, Sapienza University of Rome, via di Grottarossa 1032, 00189, Rome, Italy.
Alka BhideDepartment of Urogynaecology, Academic Department of Obstetrics and Gynaecology, St. Mary's Hospital, Imperial College Healthcare NHS Trust, Mint Wing, South Wharf, W2 1NY, London, UK.
Suzy ElneilNational Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
G Alessandro DigesuDepartment of Urogynaecology, Academic Department of Obstetrics and Gynaecology, St. Mary's Hospital, Imperial College Healthcare NHS Trust, Mint Wing, South Wharf, W2 1NY, London, UK. a.digesu@imperial.ac.uk.
Imperial College Healthcare NHS Trust · GBNational Hospital for Neurology and Neurosurgery · GBSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and hypothesisMost subjects with multiple sclerosis (MS) suffer from lower urinary tract symptoms (LUTS). Detrusor overactivity, detrusor hypocontractility and detrusor-sphincter dyssynergia are the most common bladder dysfunctions. Management is not straightforward due to the progressive course of the disease. Sacral neuromodulation (SNM) has received increasing attention among new effective treatments for bladder disorders associated with MS. The aim of this study was to review the published literature on the role of SNM in the treatment of LUTS in patients with MS.

methodsA literature search was carried out up to December 2014, using relevant search terms in MEDLINE and EMBASE databases. The ClinicalTrials.gov and Controlled-trials.com online trial registries and the abstracts from international scientific meetings were searched for English-language studies containing relevant search terms. Relevant reviews and trials and prospective studies were analysed by two independent reviewers.

resultsTwo prospective studies and four retrospective studies were included. Overall, MS patients represented small series (4 to 25 subjects). The longest follow-up was 7 years and the evaluation of the treatment outcomes was not homogeneous among the studies. The definition of objective cure was often unclear. The subjective cure rate was 45 %, patients' reported satisfaction was 85 % and all the results were stable over time.

conclusionsSNM seems to be a safe and effective treatment for LUTS in MS patients. Further and larger studies as well as randomized controlled trials are needed to confirm its clinical role in patients with MS.

Indexed as

Transcutaneous Electric Nerve StimulationHumansLower Urinary Tract SymptomsMultiple SclerosisDetrusor sphincter dyssynergiaDetrusor underactivityLower urinary tract symptomsMultiple sclerosisNeurogenic detrusor overactivitySacral neuromodulationVoiding disorders

Identifiers

PMID26156206
OpenAlexW824341687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.